Specific CD8+ T cell response immunotherapy for hepatocellular carcinoma and viral hepatitis

Table 1 Clinical trials of immune checkpoint inhibitors in patients with chronic hepatitis and hepatocellular carcinoma

NCT	Status	Disease	Agent	Result	Ref.
01008358	Completed	HCC and CHC	Tremelimumab	TTP: 6.48 m	[30]
01853618	Recruiting	HCC	Tremelimumab	TTP: 7.4 m	[111]
00703469	Completed	CHC	Nivolumab	15% significant reduction of viral load	[31]
02658019	Not yet recruiting	HCC	Pembrolizumab	NA	[112]
01658878	Recruiting	HCC	Nivolumab	NA	[113]
			Ipilimumab

Tremelimumab and ipilimumab are humanized monoclonal antibodies against CTLA-4; Nivolumab and pembrolizumab are humanized monoclonal antibodies against PD-1. HCC: Hepatocellular carcinoma; NA: Not available; NCT: Clinical trial number at clinicaltrials.gov; TTP: Time to progression.